Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model

被引：31

作者：

Banerjee, Abhisek ^{[1
]}

Patil, Sandip ^{[1
]}

Pawar, Mahesh Y. ^{[1
]}

Gullapalli, Srinivas ^{[1
]}

Gupta, Praveen K. ^{[1
]}

Gandhi, Maulik N. ^{[1
]}

Bhateja, Deepak K. ^{[1
]}

Bajpai, Malini ^{[1
]}

Sangana, Ramachandra Rao ^{[1
]}

Gudi, Girish S. ^{[1
]}

Khairatkar-Joshi, Neelima ^{[1
]}

Gharat, Laxmikant A. ^{[1
]}

机构：

[1] Glenmark Pharmaceut Ltd, Navi Mumbai 400709, Maharashtra, India

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 19期

关键词：

PDE7; Imidazopyridazinone; CNS penetration; Parkinson's disease; MPTP; Haloperidol; CAMP-SPECIFIC PHOSPHODIESTERASE; RAT STRIATUM; DISORDERS; MICE; HALOPERIDOL; EFFICACY; ROLIPRAM;

D O I：

10.1016/j.bmcl.2012.07.077

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis and structure-activity relationship studies of a series of compounds from imidazopyridazinone scaffold as PDE7 inhibitors are disclosed. Potent analogs such as compounds 7 (31 nM), 8 (27 nM), and 9 (12 nM) were identified. The PDE selectivity and pharmacokinetic profile of compounds 7, 8 and 9 are also disclosed. The adequate CNS penetration of compound 7 in mice allowed it to be tested in the MPTP induced PD model and haloperidol induced catalepsy model to probe the differential pharmacology of PDE7 in the striatal pathway. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：6286 / 6291

页数：6

共 25 条

[1] THE FUNCTIONAL-ANATOMY OF BASAL GANGLIA DISORDERS [J].

ALBIN, RL ;

YOUNG, AB ;

PENNEY, JB .

TRENDS IN NEUROSCIENCES, 1989, 12 (10) :366-375

[2] Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation [J].

Banerjee, Abhisek ;

Yadav, Pravin S. ;

Bajpai, Malini ;

Sangana, Ramachandra Rao ;

Gullapalli, Srinivas ;

Gudi, Girish S. ;

Gharat, Laxmikant A. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (09) :3223-3228

[3]

Bergmann J.E., 2010, U. S. Pat. Appl., Patent No. [US 0113486, 0113486]

[4] The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice [J].

Boulay, Denis ;

Bergis, Olivier ;

Avenet, Patrick ;

Griebel, Guy .

NEUROPSYCHOPHARMACOLOGY, 2010, 35 (02) :416-427

[5] PRIMATE MODELS OF MOVEMENT-DISORDERS OF BASAL GANGLIA ORIGIN [J].

DELONG, MR .

TRENDS IN NEUROSCIENCES, 1990, 13 (07) :281-285

[6] MPTP-INDUCED HYPOACTIVITY IN MICE - REVERSAL BY L-DOPA [J].

FREDRIKSSON, A ;

PLAZNIK, A ;

SUNDSTROM, E ;

JONSSON, G ;

ARCHER, T .

PHARMACOLOGY & TOXICOLOGY, 1990, 67 (04) :295-301

[7] Phosphodiesterase 7 (PDE7) as a therapeutic target [J].

Giembycz, Mark A. ;

Smith, Susan J. .

DRUGS OF THE FUTURE, 2006, 31 (03) :207-229

[8] PDE7 inhibitors as new drugs for neurological and inflammatory disorders [J].

Gil, Carmen ;

Campillo, Nuria E. ;

Perez, Daniel I. ;

Martinez, Ana .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (10) :1127-1139

[9] Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia [J].

Grauer, Steven M. ;

Pulito, Virginia L. ;

Navarra, Rachel L. ;

Kelly, Michele P. ;

Kelley, Cody ;

Graf, Radka ;

Langen, Barbara ;

Logue, Sheree ;

Brennan, Julie ;

Jiang, Lixin ;

Charych, Erik ;

Egerland, Ute ;

Liu, Feng ;

Marquis, Karen L. ;

Malamas, Michael ;

Hage, Thorsten ;

Comery, Thomas A. ;

Brandon, Nicholas J. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 331 (02) :574-590

[10]

Gres'ko S.V., 2001, RUSSIAN J ORG CHEM, V1026, P37

← 1 2 3 →